Canaccord Genuity Maintains a Buy on Inventiva (IVA) With a $20 Price Target
Inventiva S.A. (NASDAQ:IVA) is one of the 13 Best Long-Term Penny Stocks to Buy According to Analysts. Analyst Edward Nash from Canaccord Genuity maintained a Buy rating on Inventiva S.A. (NASDAQ:IVA) on June 5, keeping the price target at $20.00.
The rating was based on several factors, including the potential of lanifibranor, the company's lead asset in the MASH space. Lanifibranor's oral administration and direct anti-fibrotic effects distinguish it from other treatments in development, with a primary focus on liver fat reduction.
A research scientist in an idiopathic pulmonary fibrosis laboratory, carrying out clinical trials.
The analyst also reasoned that Lanifibranor can be used in conjunction with other treatments, including GLP-1s and SGLT2 inhibitors. This factor is a significant boost to its appeal, especially when considering the high prevalence of type 2 diabetes in MASH patients.
Nash stated that the drug is progressing well, which can be corroborated by the completion of full enrollment in the Phase III NATiV3 trial and the anticipated top-line data in H2 2026. Major pharmaceutical companies are also showing increasing interest in the MASH space, further supporting the optimistic outlook for Inventiva S.A. (NASDAQ:IVA).
Inventiva S.A. (NASDAQ:IVA) is a clinical-stage biopharmaceutical company that develops oral small-molecule therapies to treat non-alcoholic steatohepatitis or NASH. It also develops therapies for other diseases with considerable unmet medical needs.
While we acknowledge the potential of IVA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.
Disclosure: None.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
33 minutes ago
- Yahoo
Medtronic (MDT) Appoints Dr. Joon Sup Lee to Board of Directors
Medtronic plc (NYSE:MDT) is one of the 11 best European stocks to invest in. On June 23, the company announced the appointment of Dr. Joon Sup Lee as an independent director to its Board of Directors. The appointment went into effect on June 18, 2025. A healthcare specialist in the laboratory testing an Oncology-related product. Dr. Lee's appointment was a result of Medtronic increasing the size of its Board. The new director will serve on the Board's Science and Technology Committee and the Compensation and Talent Committee. Dr. Lee is currently the CEO of Emory Healthcare, Inc., overseeing Georgia's most comprehensive academic health system. Before joining Emory Healthcare, Dr. Lee was the executive director of the University of Pittsburgh Medical Center's (UPMC) Heart and Vascular Institute from 2018 to 2020. He was also a professor of medicine at the University of Pittsburgh School of Medicine. He held various leadership roles at UPMC, including Director of Interventional Cardiology and Director of the Cardiac Catheterization Laboratory. Medtronic plc (NYSE:MDT) is an Irish-domiciled healthcare technology company. It develops and sells medical devices and therapies for chronic conditions across four main segments: Cardiovascular, Neuroscience, Medical Surgical, and Diabetes. Its top products include heart devices, spinal implants, surgical tools, insulin pumps, and neuromodulation systems. Medtronic serves over 79 million patients annually in more than 150 countries. While we acknowledge the potential of MDT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
33 minutes ago
- Yahoo
Trane Technologies (TT) Expands Liquid Cooling Solutions for AI Data Centers
Trane Technologies plc (NYSE:TT) is one of the 11 best European stocks to invest in. On June 10, Trane announced the expansion of its liquid cooling capabilities for data centers. As part of the initiative, the company introduced new scalable Coolant Distribution Unit (CDU) solutions with capacities ranging from 2.5 megawatts (MW) to 10 MW. A technician in a boiler suit working on an industrial air conditioning system inside a factory. The new CDUs complement Trane's existing 1 MW CDU, providing a broader range of direct-to-chip cooling solutions. According to the company, the expanded platform is designed to address the high-density computing needs of data centers, particularly those driven by the increasing demand for artificial intelligence (AI) workloads. The company said that the new CDUs enable modular scalability. They are also optimized for high-density data centers, ensuring efficient heat transfer directly from IT equipment. Most importantly, the new platform offers up to 10 MW of cooling capacity in a space-saving, factory-skid-mounted design, which also facilitates ease of serviceability. Trane Technologies plc (NYSE:TT) is a climate solutions company based in Ireland. It designs, manufactures, and services energy-efficient heating, ventilation, air conditioning (HVAC), and refrigeration systems. Its key brands are Trane (for buildings and homes) and Thermo King (for transport refrigeration). The company operates across the Americas, EMEA, and Asia Pacific. While we acknowledge the potential of TT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None.
Yahoo
38 minutes ago
- Yahoo
H.C. Wainwright Reiterated a Buy Rating on Redwire Corporation (RDW), Kept the PT Unchanged
Redwire Corporation (NYSE:RDW) is one of the . On June 24, Analyst Scott Buck from H.C. Wainwright reiterated a Buy rating on Redwire Corporation (NYSE:RDW) with a $26.00 price target. The bullish sentiment is based on the acquisition of Edge Autonomy made by the company. On June 13, Redwire Corporation (NYSE:RDW) announced the acquisition of Edge Autonomy, a leading provider of uncrewed airborne system technology. This strategic transaction transforms the company into an aerospace and defense technology company focused on integrated autonomous operations for defense and national security. Moreover, the acquisition also expands the company's global manufacturing and innovation footprint, adding over 1,300 skilled employees and more than 628,000 square feet of manufacturing facilities across the US and Europe. A close-up of an antenna, its intricate designs a testament to the company's expertise in space infrastructure. Analyst Scott Buck believes the acquisition will immediately boost Redwire Corporation's (NYSE:RDW) revenue, EBITDA, and free cash flow. Moreover, the analyst expects the integration to be swift, enabling the company to capitalize on immediate opportunities, particularly in Europe, where defense budgets are projected to increase. While we acknowledge the potential of RDW as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Sign in to access your portfolio
